Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients

BMC Cardiovasc Disord. 2009 Aug 26:9:41. doi: 10.1186/1471-2261-9-41.

Abstract

Background: Dyslipidemia, particularly hypertriglyceridemia is common in uremia, and represents an independent risk factor for atherosclerosis.

Methods: To investigate the effects of hemodialysis (HD) duration on very low density lipoprotein (VLDL) and low density lipoprotein (LDL) compositions and lipopolytic activities, 20 patients on 5 to 7 years hemodialysis were followed-up during 9 years. Blood samples were drawn at T0 (beginning of the study), T1 (3 years after initiating study), T2 (6 years after initiating study) and T3 (9 years after initiating study). T0 was taken as reference.

Results: Triacylglycerols (TG) values were correlated with HD duration (r = 0.70, P < 0.05). An increase of total cholesterol was noted at T2 and T3. Lowered activity was observed for lipoprotein lipase (LPL) (-44%) at T3 and hepatic lipase (HL) (-29%) at T1, (-64%) at T2 and (-73%) at T3. Inverse relationships were found between HD duration and LPL activity (r = -0.63, P < 0.05), and HL activity (r = -0.71, P < 0.01). At T1, T2 and T3, high VLDL-amounts and VLDL-TG and decreased VLDL-phospholipids values were noted. Increased LDL-cholesteryl esters values were noted at T1 and T2 and in LDL-unesterified cholesterol at T2 and T3.

Conclusion: Despite hemodialysis duration, VLDL-LDL metabolism alterations are aggravated submitting patients to a greater risk of atherosclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apolipoprotein C-II / blood
  • Apolipoprotein C-III / blood
  • Atherosclerosis / blood
  • Atherosclerosis / etiology*
  • Biomarkers / blood
  • Cholesterol / blood
  • Dyslipidemias / blood
  • Dyslipidemias / etiology*
  • Female
  • Humans
  • Insulin / blood
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy*
  • Linear Models
  • Lipase / blood
  • Lipolysis*
  • Lipoprotein Lipase / blood
  • Lipoproteins, LDL / blood*
  • Lipoproteins, VLDL / blood*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Renal Dialysis / adverse effects*
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Triglycerides / blood

Substances

  • Apolipoprotein C-II
  • Apolipoprotein C-III
  • Biomarkers
  • Insulin
  • LIPC protein, human
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Triglycerides
  • Cholesterol
  • Lipase
  • Lipoprotein Lipase